Blephamide Generic Name & Formulations
Sulfacetamide sodium 10%, prednisolone acetate 0.2%; oph susp; contains benzalkonium chloride.
Sulfonamide + steroid.
Susp—5mL, 10mL; Oint—3.5g
Ocular inflammation with infection.
Blephamide Dosage and Administration
Adults and Children
<6yrs: not established. ≥6yrs: 2 drops every 4 hours and at bedtime or small amount of ointment 3–4 times daily and 1–2 times at night. May prolong dosing interval as condition improves; max 20mL or 8g per therapeutic course. Re-evaluate if no improvement after 2 days.
Ocular fungal, viral, or mycobacterial infections.
Blephamide Boxed Warnings
Corneal or scleral thinning: increased risk of perforation. Glaucoma. Severe dry eye. Purulent exudates may inactivate sulfonamides. Cataract surgery: may delay healing and increase bleb formation. May mask signs of infection. Monitor for secondary ocular infections (eg, fungal) and intraocular pressure in prolonged use (≥10 days). Discontinue if rash or hypersensitivity reactions occur. Avoid abrupt cessation. Pregnancy. Nursing mothers: not recommended.
Renal. Half-life: 7–12.8 hours (sulfacetamide), 2–3 hours (prednisolone).
Incompatible with silver-containing preparations. Antagonized by PABA.
Blephamide Adverse Reactions
Ocular irritation, secondary ocular infections; rare: severe sulfonamide reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, blood dyscrasias). In prolonged use: increased IOP, cataracts, optic nerve damage.
Blephamide Clinical Trials
Blephamide Patient Counseling